iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology ...
– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets – BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision …